low - Specialty pharmaceuticals for serious autoimmune diseases exhibit minimal GDP sensitivity as treatment decisions are medically driven rather than discretionary. Lupus nephritis patients require therapy regardless of economic conditions, and insurance coverage (primarily Medicare/Medicaid and commercial plans) insulates demand from consumer spending cycles. However, severe recessions could pressure payer reimbursement rates or prior authorization requirements.

Rising rates create modest headwinds through higher discount rates applied to future cash flows in DCF valuations, particularly impactful for growth-stage biopharma with profitability inflection points. The company's $360M cash position (implied by 5.76x current ratio and minimal debt) generates higher interest income in rising rate environments, partially offsetting valuation compression. Financing costs are minimal given 0.21 debt/equity ratio.

growth - The 79% one-year return and 34% revenue growth attract growth investors focused on commercial-stage biopharma with inflection to profitability. The recent achievement of positive net margins (2.4%) and operating margins near breakeven (-2%) appeals to investors seeking de-risked growth stories with visible paths to sustained profitability. Momentum investors have driven recent performance, though 7.7% three-month decline suggests profit-taking after strong run.